Elan Corp. of Dublin, Ireland and its American subsidiary Eisai Co. have to pay $214 million to resolve allegations that they illegally promoted the epilepsy drug Zonegran. Elan Pharmaceuticals Inc., agreed to plead guilty to a misdemeanor criminal charge of misbranding the drug. Elan promoted Zonegran for a wide variety of uses not approved by the FDA, including mood stabilization, migraine and chronic headaches, weight loss and seizures. Elan's efforts targeted non-epilepsy prescribers and the company paid illegal kickbacks to physicians in an effort to persuade them to prescribe the drug for so-called off-label uses.
Elan's general counsel, John Moriarty Jr., said "Elan is committed to adhering to the highest ethical and legal standards and has developed a strong compliance program based upon best industry practices". Link here
No comments:
Post a Comment